Hear an organization's experience with being trained to use Amplifi ID, and their plans to use it with their drug checking service.

Learn more about Spectra Plasmonics and the Amplifi ID Drug Checking Technology.

BTMPS was not designed or approved for human or animal consumption, yet has been appearing in the US drug supply.

Stories from frontline healthcare groups using Amplifi ID for Drug Checking.

Learn the difference between Raman and FTIR, and how these relate to your Drug Checking program.

Xylazine Background Rates of xylazine adulteration have increased throughout the unregulated drug supply in the United States. Xylazine...

Here's what you need to know about preparing drug samples for testing with Amplifi ID. 

Read a short excerpt from our newest case study on NorWest CHC and how Amplifi ID elevated their harm reduction programming:

In this blog post, we will delve into noteworthy street drugs and their potential health risks to users.

This post will go over how bulk scan works and the benefits this new scan type provides.

Here our Spectra's key takeaways from NHRC's Harm Reduction Funding e-Course

Interview with Dr. Monty Ghosh to discuss harm reduction and treatment programming as well as the impact of drug checking.

Spectra was an exhibitor at the 2023 Rx and Illicit Drugs Summit in Atlanta this month. Here are the biggest takeaways from the conference.

Amplifi ID can conduct two types of scans; bulk and trace to help obtain a detailed breakdown of components in a drug sample.

Spectra Plasmonics had the opportunity to sit down with Matt Bonn, a program manager with the Canadian Association of People Who Use Drugs.

From simple test strips to more complex spectroscopic methods, there are a variety of tools available to help assess the quality of drugs

Spectra Plasmonics had the opportunity to sit down with Brandon Kober, a former harm reduction nurse, to learn more about harm reduction...